Kenji Sugio Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

5/2022	A prospective observational study of postoperative adjuvant chemotherapy for non-small cell lung cancer in elderly patients (≥ 75 years).
1/2022	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
1/2022	Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
3/2021	A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
1/2021	Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
1/2021	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
1/2021	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
12/2020	A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
12/2020	Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
5/2020	A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenji Sugio Research Topics

Disease

68	Neoplasms (Cancer) 01/2022 - 01/2002
45	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022 - 07/2002
39	Lung Neoplasms (Lung Cancer) 07/2021 - 01/2002
15	Neoplasm Metastasis (Metastasis) 12/2021 - 06/2002
13	Adenocarcinoma 01/2018 - 01/2002
8	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 05/2002
8	Carcinoma (Carcinomatosis) 09/2016 - 04/2003
6	Breast Neoplasms (Breast Cancer) 07/2020 - 08/2003
6	Adenocarcinoma of Lung 04/2019 - 01/2002
5	Disease Progression 01/2021 - 01/2005
3	Neoplasm Micrometastasis 11/2014 - 01/2002
3	Lymphoma (Lymphomas) 07/2014 - 08/2002
3	Carcinogenesis 03/2013 - 07/2005
3	Lymphatic Metastasis 08/2009 - 10/2006
3	Large Cell Carcinoma 03/2007 - 09/2005
3	Melanoma (Melanoma, Malignant) 04/2006 - 07/2002
3	Esophageal Neoplasms (Esophageal Cancer) 09/2005 - 05/2005
2	Thymoma (Thymic Carcinoma) 01/2020 - 03/2002
2	Febrile Neutropenia 01/2020 - 07/2016
2	Anemia 01/2020 - 10/2018
2	Brain Neoplasms (Brain Tumor) 04/2019 - 01/2009
2	Meningeal Carcinomatosis 04/2019 - 01/2009
2	Malignant Mesothelioma 09/2016 - 07/2009
2	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 06/2002
2	Pleural Effusion (Pleural Effusions) 03/2014 - 04/2003
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 07/2009 - 09/2007
2	Esophageal Squamous Cell Carcinoma 05/2009 - 07/2007
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2004 - 11/2003
1	Aggressive Fibromatosis (Desmoid) 01/2021
1	Fibroma (Fibromatosis) 01/2021

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 06/2018 - 04/2004
12	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2006
11	AntigensIBA 07/2009 - 03/2002
10	Gefitinib (Iressa)FDA Link 01/2022 - 01/2006
9	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2009
7	Pemetrexed (MTA)FDA Link 01/2022 - 09/2016
6	ParaffinIBA 01/2021 - 10/2004
6	Tyrosine Kinase InhibitorsIBA 01/2021 - 12/2006
6	Neoplasm Antigens (Tumor Antigens)IBA 09/2006 - 03/2002
5	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022 - 01/2020
5	osimertinibIBA 12/2021 - 05/2020
5	Biological ProductsIBA 08/2009 - 05/2003
5	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 05/2008 - 03/2003
4	PlatinumIBA 01/2022 - 10/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2002
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2020 - 07/2007
4	Peptides (Polypeptides)IBA 03/2007 - 04/2004
4	Immunoglobulin G (IgG)IBA 09/2006 - 03/2002
4	Cadherins (E-Cadherin)IBA 01/2006 - 01/2002
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2020
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2020
3	S-1 plus cisplatinIBA 01/2020 - 11/2013
3	Pharmaceutical PreparationsIBA 04/2019 - 01/2007
3	Carcinoembryonic AntigenIBA 01/2016 - 03/2005
3	CateninsIBA 05/2009 - 03/2002
3	Indicators and Reagents (Reagents)IBA 05/2009 - 12/2004
3	Estrogens (Estrogen)FDA Link 01/2009 - 07/2007
3	Histidine (L-Histidine)FDA Link 05/2006 - 04/2004
3	beta CateninIBA 01/2006 - 01/2002
3	Tumor Biomarkers (Tumor Markers)IBA 03/2005 - 01/2003
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
2	TegafurIBA 12/2020 - 11/2013
2	alectinibIBA 01/2020 - 01/2017
2	Bevacizumab (Avastin)FDA Link 04/2019 - 01/2019
2	B7-H1 AntigenIBA 06/2018 - 01/2018
2	CarcinogensIBA 01/2018 - 03/2003
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 07/2016
2	Phosphotransferases (Kinase)IBA 07/2014 - 01/2010
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 07/2014 - 01/2010
2	ProdrugsIBA 11/2013 - 01/2007
2	AsbestosIBA 07/2009 - 04/2003
2	AntibodiesIBA 07/2009 - 03/2002
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2009 - 01/2006
2	Aromatase (CYP19)IBA 01/2009 - 05/2008
2	Messenger RNA (mRNA)IBA 09/2007 - 08/2003
2	CytokinesIBA 07/2007 - 01/2002
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 05/2007 - 01/2007
2	CytochromesIBA 05/2007 - 03/2003
2	HLA-A24 AntigenIBA 03/2007 - 05/2005
2	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 01/2007 - 03/2003
2	Cytochrome P-450 CYP3AIBA 01/2007 - 05/2005
2	Cytochrome P-450 CYP2E1 (CYP2E1)IBA 01/2007 - 03/2003
2	Complementary DNA (cDNA)IBA 09/2006 - 03/2002
2	PhytohemagglutininsIBA 05/2006 - 07/2005
2	Amino Acids FDA Link 05/2006 - 04/2004
2	alpha Catenin (alpha E-Catenin)IBA 01/2006 - 03/2002
2	Keratins (Keratin)IBA 07/2002 - 01/2002
1	Cell-Free Nucleic AcidsIBA 07/2021
1	Nucleic AcidsIBA 07/2021
1	Formaldehyde (Formol)FDA Link 01/2021

Therapy/Procedure

15	Therapeutics 01/2022 - 06/2002
13	Drug Therapy (Chemotherapy) 01/2022 - 05/2005
10	Radiotherapy 12/2021 - 01/2009
7	Adjuvant Chemotherapy 05/2022 - 11/2014
5	Immunotherapy 11/2007 - 07/2002
4	Chemoradiotherapy 11/2013 - 05/2010
2	Segmental Mastectomy (Lumpectomy) 11/2020 - 06/2002
2	Ventriculoperitoneal Shunt 12/2016 - 01/2009
2	Metastasectomy 01/2016 - 06/2002
2	Lymph Node Excision (Lymph Node Dissection) 12/2015 - 06/2002